Table 1.

DDC-related proteins targeted in cancer therapy.

DDC Pathway
Protein	Drug Name	Combined Treatment	Possible Synthetic Lethal Interaction	Clinical Trial	References
ATM	AZD0156	Ionizing radiation Topoisomerase I and II inhibitors	PARP1 inhibition	NCT02588105	[105,106,107,108]
	AZD1390			NCT03423628
	KU-55933
	KU-60019
	KU-59403
ATR	M6620	Ionizing radiation Cisplatin	ATM inhibition	NCT02589522 NCT02567422	[115,116,117,118,119,120,121,122,123]
	AZD6738	Ionizing radiation	ATM inhibition WEE1 inhibition
	BAY1895344	Ionizing radiation Cisplatin	ATM inhibition PARP1 inhibition
	VE-821	Ionizing radiation Anti-metabolites	ATM inhibition CHK1 inhibition
DNA-PK	M3814	Topoisomerase I and II inhibitors Anti-metabolites Ionizing radiation	ATM inhibition	NCT03770689	[109,110,111,112,113]
	VX-984	Ionizing radiation Topoisomerase I and II inhibitors		NCT02644278
	CC-115	Ionizing radiation		NCT02516813
	MSC2490484A	Ionizing radiation		NCT02833883
CHK1	AZD7762	Anti-metabolites	ATR inhibition	NCT00937664	[120]
	MK-8776		FANCD2 inhibition		[124]
WEE1	AZD1775	Cisplatin Ionizing radiation	PARP1 inhibition	NCT03028766	[119]

For each target it is reported the name of the drugs currently in analysis; combination of target inhibition and classic anti-cancer therapy under study; possible synthetic lethality interaction; ongoing clinical trials with the drugs; references.